PMID- 35900204
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220731
IS  - 2058-5241 (Print)
IS  - 2058-5241 (Electronic)
IS  - 2058-5241 (Linking)
VI  - 7
IP  - 7
DP  - 2022 Jul 5
TI  - Does anti-nerve growth factor monoclonal antibody treatment have the potential to 
      replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee 
      osteoarthritis? A systematic review of randomized controlled trials.
PG  - 470-480
LID - 10.1530/EOR-21-0103 [doi]
AB  - PURPOSE: Considering the adverse effects of nonsteroidal anti-inflammatory drugs 
      (NSAIDs) and opioids for treating osteoarthritis (OA), development of drugs that 
      are more effective and better tolerated than existing treatments is urgently 
      needed. This systematic review aimed to evaluate the efficacy and safety of 
      anti-nerve growth factor (NGF) monoclonal antibodies vs active comparator 
      therapy, such as NSAIDs and oxycodone, in treating hip or knee OA. METHODS: 
      Databases were comprehensively searched for randomized controlled trials (RCTs) 
      published before January 2022. Efficacy and safety outcomes were assessed. 
      RESULTS: Six RCTs that included 4325 patients were identified. Almost all the 
      RCTs indicated that moderate doses of anti-NGF monoclonal antibody treatment 
      significantly improved efficacy outcomes based on the Western Ontario and 
      McMaster Universities Osteoarthritis Index (WOMAC) pain score, the WOMAC physical 
      function score and the Patient's Global Assessment compared with those of the 
      active comparator. At least half of the RCTs indicated that the incidence of 
      severe adverse events, withdrawals due to adverse events (AEs) and total joint 
      replacement were not significantly different between anti-NGF monoclonal antibody 
      treatment and active comparator therapy, but the outcomes of some studies may 
      have been limited by a short duration of follow-up. Most RCTs suggested that 
      anti-NGF monoclonal antibody treatment had a lower incidence of gastrointestinal 
      and cardiovascular AEs. However, the majority of RCTs reported a higher incidence 
      of abnormal peripheral sensation with anti-NGF monoclonal antibody treatment. 
      Furthermore, the higher incidence of rapidly progressive osteoarthritis (RPOA) 
      with anti-NGF monoclonal antibody treatment should also not be overlooked, and 
      the identification of patient characteristics that increase the risk of RPOA is 
      critical in further studies. CONCLUSION: Based on the current research evidence, 
      anti-NGF monoclonal antibodies are not yet a replacement for analgesic drugs such 
      as NSAIDs but might be a new treatment option for hip or knee OA patients who are 
      intolerant or unresponsive to nonopioid or opioid treatment. Notably, however, 
      considering the inconsistency and inconclusive evidence on the safety outcomes of 
      recent studies, more research is needed, and long-term follow-up is required.
FAU - Zhao, Di
AU  - Zhao D
AD  - The Second Clinical School of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Zeng, Ling-Feng
AU  - Zeng LF
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Liang, Gui-Hong
AU  - Liang GH
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
FAU - Pan, Jian-Ke
AU  - Pan JK
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Luo, Ming-Hui
AU  - Luo MH
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Han, Yan-Hong
AU  - Han YH
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Liu, Jun
AU  - Liu J
AUID- ORCID: 0000-0002-2440-4064
AD  - Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial 
      Academy of Chinese Medical Sciences, Guangzhou, China.
AD  - Guangdong Second Traditional Chinese Medicine Hospital (Guangdong Province 
      Engineering Technology Research Institute of Traditional Chinese Medicine), 
      Guangzhou, China.
AD  - The fifth Clinical Medical College of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Yang, Wei-Yi
AU  - Yang WY
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220705
PL  - England
TA  - EFORT Open Rev
JT  - EFORT open reviews
JID - 101695674
PMC - PMC9297056
OTO - NOTNLM
OT  - OA
OT  - anti-NGF monoclonal antibody
OT  - osteoarthritis
OT  - randomized controlled trials
OT  - systematic review
EDAT- 2022/07/29 06:00
MHDA- 2022/07/29 06:01
PMCR- 2022/07/05
CRDT- 2022/07/28 09:53
PHST- 2022/07/28 09:53 [entrez]
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/07/29 06:01 [medline]
PHST- 2022/07/05 00:00 [pmc-release]
AID - EOR-21-0103 [pii]
AID - 10.1530/EOR-21-0103 [doi]
PST - epublish
SO  - EFORT Open Rev. 2022 Jul 5;7(7):470-480. doi: 10.1530/EOR-21-0103.